scholarly journals Synergistic activity of BET protein antagonist-based combinations in mantle cell lymphoma cells sensitive or resistant to ibrutinib

Blood ◽  
2015 ◽  
Vol 126 (13) ◽  
pp. 1565-1574 ◽  
Author(s):  
Baohua Sun ◽  
Bhavin Shah ◽  
Warren Fiskus ◽  
Jun Qi ◽  
Kimal Rajapakshe ◽  
...  
Keyword(s):  
Mantle Cell Lymphoma ◽  
Histone Deacetylases ◽  
Cell Lymphoma ◽  
Synergistic Activity ◽  
Lymphoma Cells ◽  
Key Points ◽  
Mantle Cell ◽  
Bet Protein

Key Points BA reduces MYC, CDK4/6, nuclear RelA, and BTK expression and is synergistically lethal with ibrutinib in MCL cells. Cotreatment with BA and inhibitor of BCL2, CDK4/6, or histone deacetylases is synergistically lethal against ibrutinib-resistant MCL cells.

BET protein proteolysis targeting chimera (PROTAC) exerts potent lethal activity against mantle cell lymphoma cells

Leukemia ◽  
2017 ◽  
Vol 32 (2) ◽  
pp. 343-352 ◽  
Author(s):  
B Sun ◽  
W Fiskus ◽  
Y Qian ◽  
K Rajapakshe ◽  
K Raina ◽  
...  
Keyword(s):  
Mantle Cell Lymphoma ◽  
Cell Lymphoma ◽  
Lymphoma Cells ◽  
Mantle Cell ◽  
Bet Protein

scholarly journals Phase 2 study of VcR-CVAD with maintenance rituximab for untreated mantle cell lymphoma: an Eastern Cooperative Oncology Group study (E1405)

Blood ◽  
2014 ◽  
Vol 123 (11) ◽  
pp. 1665-1673 ◽  
Author(s):  
Julie E. Chang ◽  
Hailun Li ◽  
Mitchell R. Smith ◽  
Randy D. Gascoyne ◽  
Elisabeth M. Paietta ◽  
...  
Keyword(s):  
Mantle Cell Lymphoma ◽  
Cell Lymphoma ◽  
Eastern Cooperative Oncology Group ◽  
Phase 2 ◽  
Oncology Group ◽  
Oncology Group Study ◽  
Phase 2 Study ◽  
Key Points ◽  
Mantle Cell

Key Points VcR-CVAD produced high overall and CR rates in previously untreated MCL patients. No substantial difference in 3-year PFS or OS was observed in patients receiving ASCT compared with patients receiving maintenance rituximab.

scholarly journals The G protein-coupled estrogen receptor 1 (GPER-1) contributes to the proliferation and survival of mantle cell lymphoma cells

Haematologica ◽  
2015 ◽  
Vol 100 (11) ◽  
pp. e458-e461 ◽  
Author(s):  
M. Rudelius ◽  
H. Rauert-Wunderlich ◽  
E. Hartmann ◽  
E. Hoster ◽  
M. Dreyling ◽  
...  
Keyword(s):  
Estrogen Receptor ◽  
Mantle Cell Lymphoma ◽  
G Protein ◽  
Cell Lymphoma ◽  
Lymphoma Cells ◽  
Mantle Cell ◽  
G Protein Coupled ◽  
Estrogen Receptor 1

scholarly journals High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma

Blood ◽  
2015 ◽  
Vol 126 (5) ◽  
pp. 604-611 ◽  
Author(s):  
Marie-Hélène Delfau-Larue ◽  
Wolfram Klapper ◽  
Françoise Berger ◽  
Fabrice Jardin ◽  
Josette Briere ◽  
...  
Keyword(s):  
Mantle Cell Lymphoma ◽  
Prognostic Value ◽  
Cell Lymphoma ◽  
Standard Of Care ◽  
High Dose ◽  
Current Standard ◽  
Ki 67 ◽  
Key Points ◽  
Mantle Cell ◽  
High Dose Cytarabine

Key Points CDKN2A and TP53 deletions remain of bad prognostic value in younger MCL patients treated according to the current standard of care. CDKN2A and TP53 deletions have independent deleterious effects and should be considered for treatment decisions in addition to MIPI and Ki-67 index.

scholarly journals TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy

Blood ◽  
2017 ◽  
Vol 130 (17) ◽  
pp. 1903-1910 ◽  
Author(s):  
Christian W. Eskelund ◽  
Christina Dahl ◽  
Jakob W. Hansen ◽  
Maj Westman ◽  
Arne Kolstad ◽  
...  
Keyword(s):  
Mantle Cell Lymphoma ◽  
Cell Lymphoma ◽  
Standard Of Care ◽  
Younger Patients ◽  
Tp53 Mutations ◽  
Key Points ◽  
Mantle Cell ◽  
Frontline Treatment

Key Points The intensified standard-of-care regimens for younger patients with MCL do not overcome the deleterious effects of TP53 mutations. MCLs with TP53 mutations should be considered for alternative frontline treatment.

Sign in / Sign up

Export Citation Format

Share Document